Gene or Genome – Page 7

RFK Jr. Fires Top HHS Leadership in Major Department Shakeup

5 months ago talkbio0Tagged Buckham, CHARGE Syndrome, Hannah Anderson, Health Policy, Heather Flick Melanson, Leadership, RFK Jr., Shakeup, Staff, TMEM79 gene, White House liaison

RFK Jr.; HHS; leadership shakeup; chief of staff replaced; Heather Flick Melanson; Hannah Anderson; Matt Buckham; health policy; White House liaison

RFK Jr. Reshuffles Top HHS Leadership, Replacing Chief of Staff and Deputy Chief

5 months ago talkbio0Tagged Buckham, Changing, CHARGE Syndrome, chief of, federal, Hannah Anderson, Health Policy, Heather Flick Melanson, Leadership, RFK Jr., Shakeup, Staff, TMEM79 gene

RFK Jr.; HHS; leadership shakeup; chief of staff; Heather Flick Melanson; Hannah Anderson; Matt Buckham; staff changes; federal health policy

RFK Jr. Fires Top Deputies, Reshuffles Leadership at HHS

5 months ago talkbio0Tagged Buckham, Changing, chief of, Hannah Anderson, Health, Heather Flick Melanson, Leadership, Research Personnel, reshuffle, Robert F. Kennedy Jr., Social Welfare, Staff, TMEM79 gene, Trump loyalists

Robert F. Kennedy Jr.; Health and Human Services; leadership reshuffle; chief of staff; personnel changes; Matt Buckham; Trump loyalists; Heather Flick Melanson; Hannah Anderson

RFK Jr. Reshuffles Top HHS Leadership, Names New Acting Chief of Staff

5 months ago talkbio0Tagged Buckham, Changing, CHARGE Syndrome, chief of, Department of Health and, Hannah Anderson, Health Policy, Heather Flick Melanson, Homo sapiens, Leadership, Research Personnel, RFK Jr., Shakeup, Staff, TMEM79 gene

RFK Jr.; HHS; leadership shakeup; chief of staff; personnel changes; Matt Buckham; Heather Flick Melanson; Hannah Anderson; health policy; Department of Health and Human Services

RFK Jr. Reshuffles Top Leadership at HHS, Replaces Chief of Staff and Deputy Policy Chief

5 months ago talkbio0Tagged Changing, CHARGE Syndrome, Healthy, Heather Flick Melanson, leadership shakeup, Matt Buckham, Research Personnel, RFK gene, Staff

RFK Jr.; HHS leadership shakeup; chief of staff replaced; Heather Flick Melanson; Hannah Anderson; Matt Buckham; personnel changes; Make America Healthy Again

WHO to Develop Guidelines for Gilead’s Twice-Yearly HIV PrEP Injection (Lenacapavir)

5 months ago talkbio0Tagged Approved, Gilead, Guidelines, HIV Prevention, Lenacapavir, PREP gene, twice-yearly injection, United States Food and Drug Administration, World Health Organization

WHO; Gilead; Lenacapavir; twice-yearly injection; PrEP; HIV prevention; guidelines; FDA approval

AstraZeneca’s Alexion Signs $825M AAV Capsid Deal with JCR Pharma

5 months ago talkbio0Tagged AAVS1 gene, Alexion, AstraZeneca, Capsid, gene therapy, genomic medicines, Infrequent, JCR, JUST-AAV, Licensing Deal

AstraZeneca; Alexion; JCR Pharmaceuticals; JUST-AAV; gene therapy; AAV capsid; rare disease; licensing deal; genomic medicines

TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects

6 months ago talkbio0Tagged Arcus Biosciences, Clinical Trials, Gilead, immuno-oncology, iTeos, Merck, Myers, Novartis, Pharma, Roche (company), SmithKline Beecham, squibb, TIGIT gene, Tiragolumab

TIGIT; immuno-oncology; failed clinical trials; pharma investment loss; Gilead; GSK; Bristol Myers Squibb; Novartis; Merck; Roche; iTeos; Arcus Biosciences; tiragolumab; belrestotug

Kymera Snags Gilead as New Partner; Sanofi Opts for Next-Gen IRAK4 Degrader

6 months ago talkbio0Tagged biotech collaborations, CDK2 protein, human, Degrader, Gilead Sciences, IRAK4 gene, Kymera, Malignant neoplasm of breast, Molecular Glue Degrader, oncology partnership, sanofi, Solid Neoplasm

Kymera Therapeutics; Gilead Sciences; Sanofi; molecular glue degrader; CDK2; solid tumors; breast cancer; oncology partnership; IRAK4 degrader; biotech collaborations

Gilead Wins Groundbreaking FDA Approval for Twice-Yearly HIV Prevention Shot

6 months ago talkbio0Tagged Approved, Gilead, Guidelines, HIV Prevention, Lenacapavir, Long-acting injectable, PREP gene, twice-yearly injection, United States Food and Drug Administration, World Health Organization, Yeztugo

Gilead; FDA approval; lenacapavir; Yeztugo; HIV prevention; twice-yearly injection; PrEP; long-acting injectable; WHO guidelines